Mitsui Chemicals invests in drug discovery company ‘Zafrens’

Zafrens has developed an ultrahigh-throughput single cell platform to isolate, image, run assays

Mitsui Chemicals announced that it has invested in Zafrens, a company supporting drug discovery through high-throughput single-cell analysis, via 321FORCE Global Innovation Fund.

Zafrens has developed an ultrahigh-throughput single cell platform to isolate, image, run assays on and sequence 50,000–200,000 cells per experiment. This platform makes it possible to understand cell behavior and decode how a cell’s molecular profile (DNA, RNA, protein) translates to its function at scale. Further, the platform’s ability to seamlessly span different therapeutic modalities allows it to rapidly generate deep insights.